NUWE
Nuwellis, Inc.
Medical - Devices
Market Cap$2M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NUWE vs ANGO
Revenue, margins, valuation, and 5-year total return — side by side.
ANGO
AngioDynamics, Inc.
Medical - Instruments & Supplies
Market Cap$469M
5Y Perf.+10.4%
NUWE vs ANGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NUWE | ANGO |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $2M | $469M |
| Revenue (TTM) | $8M | $307M |
| Net Income (TTM) | $-18M | $-28M |
| Gross Margin | 62.0% | 53.7% |
| Operating Margin | -134.3% | -9.4% |
| Total Debt | $328K | $0.00 |
| Cash & Equiv. | $1M | $56M |
NUWE vs ANGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NUWE
ANGO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Nuwellis, Inc. (NUWE) | 100 | 0.0 | -100.0% |
| AngioDynamics, Inc. (ANGO) | 100 | 110.4 | +10.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NUWE vs ANGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANGO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Nuwellis, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NUWE
Nuwellis, Inc.
The Income Pick
NUWE is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.11
- Lower volatility, beta 1.11, Low D/E 12.5%, current ratio 1.71x
- Beta 1.11, current ratio 1.71x
Best for: income & stability and sleep-well-at-night
ANGO
AngioDynamics, Inc.
The Growth Play
ANGO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -3.8%, EPS growth 81.9%, 3Y rev CAGR -2.6%
- -9.2% 10Y total return vs NUWE's -100.0%
- -3.8% revenue growth vs NUWE's -5.4%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ANGO | -3.8% revenue growth vs NUWE's -5.4% |
| Quality / Margins | ANGO | -9.0% margin vs NUWE's -211.9% |
| Stability / Safety | NUWE | Beta 1.11 vs ANGO's 1.32 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ANGO | +28.5% vs NUWE's -97.2% |
| Efficiency (ROA) | ANGO | -10.3% ROA vs NUWE's -231.2%, ROIC -22.9% vs -433.0% |
NUWE vs ANGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
NUWE vs ANGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLANGOLAGGINGNUWE
NUWENuwellis, Inc.
0leads
ANGOAngioDynamics, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs NUWEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ANGO5/6
Valuation MetricsMultiples, price ratios, and targets
ANGO2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ANGO7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ANGO6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ANGO leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ANGO is the larger business by revenue, generating $307M annually — 37.2x NUWE's $8M. Profitability is closely matched — net margins range from -9.0% (ANGO) to -2.1% (NUWE). On growth, ANGO holds the edge at +9.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NUWENuwellis, Inc. | ANGOAngioDynamics, In… |
|---|---|---|
| RevenueTrailing 12 months | $8M | $307M |
| EBITDAEarnings before interest/tax | -$8M | -$5M |
| Net IncomeAfter-tax profit | -$18M | -$28M |
| Free Cash FlowCash after capex | -$11M | -$9M |
| Gross MarginGross profit ÷ Revenue | +62.0% | +53.7% |
| Operating MarginEBIT ÷ Revenue | -134.3% | -9.4% |
| Net MarginNet income ÷ Revenue | -2.1% | -9.0% |
| FCF MarginFCF ÷ Revenue | -131.8% | -3.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.4% | +9.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.4% | +42.3% |
ANGO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
ANGO leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | NUWENuwellis, Inc. | ANGOAngioDynamics, In… |
|---|---|---|
| Market CapShares × price | $2M | $469M |
| Enterprise ValueMkt cap + debt − cash | $1M | $413M |
| Trailing P/EPrice ÷ TTM EPS | -0.04x | -13.58x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.22x | 1.60x |
| Price / BookPrice ÷ Book value/share | 2.89x | 2.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
ANGO leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ANGO leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ANGO delivers a -15.7% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-60 for NUWE. On the Piotroski fundamental quality scale (0–9), ANGO scores 5/9 vs NUWE's 3/9, reflecting solid financial health.
| Metric | NUWENuwellis, Inc. | ANGOAngioDynamics, In… |
|---|---|---|
| ROE (TTM)Return on equity | -60.5% | -15.7% |
| ROA (TTM)Return on assets | -2.3% | -10.3% |
| ROICReturn on invested capital | -4.3% | -22.9% |
| ROCEReturn on capital employed | -2.1% | -18.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.13x | — |
| Net DebtTotal debt minus cash | -$757,000 | -$56M |
| Cash & Equiv.Liquid assets | $1M | $56M |
| Total DebtShort + long-term debt | $328,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -0.75x | -258.19x |
ANGO leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ANGO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANGO five years ago would be worth $4,674 today (with dividends reinvested), compared to $0 for NUWE. Over the past 12 months, ANGO leads with a +28.5% total return vs NUWE's -97.2%. The 3-year compound annual growth rate (CAGR) favors ANGO at 7.9% vs NUWE's -94.5% — a key indicator of consistent wealth creation.
| Metric | NUWENuwellis, Inc. | ANGOAngioDynamics, In… |
|---|---|---|
| YTD ReturnYear-to-date | -39.2% | -11.1% |
| 1-Year ReturnPast 12 months | -97.2% | +28.5% |
| 3-Year ReturnCumulative with dividends | -100.0% | +25.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | -53.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -9.2% |
| CAGR (3Y)Annualised 3-year return | -94.5% | +7.9% |
ANGO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NUWE and ANGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
NUWE is the less volatile stock with a 1.11 beta — it tends to amplify market swings less than ANGO's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ANGO currently trades 80.6% from its 52-week high vs NUWE's 2.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NUWENuwellis, Inc. | ANGOAngioDynamics, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 1.32x |
| 52-Week HighHighest price in past year | $43.26 | $13.99 |
| 52-Week LowLowest price in past year | $0.96 | $8.36 |
| % of 52W HighCurrent price vs 52-week peak | +2.5% | +80.6% |
| RSI (14)Momentum oscillator 0–100 | 41.8 | 54.0 |
| Avg Volume (50D)Average daily shares traded | 61K | 395K |
Evenly matched — NUWE and ANGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NUWENuwellis, Inc. | ANGOAngioDynamics, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $16.50 |
| # AnalystsCovering analysts | — | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
ANGO leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallAngioDynamics, Inc. (ANGO)Leads 4 of 6 categories
Loading custom metrics...
NUWE vs ANGO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NUWE or ANGO a better buy right now?
For growth investors, AngioDynamics, Inc.
(ANGO) is the stronger pick with -3. 8% revenue growth year-over-year, versus -5. 4% for Nuwellis, Inc. (NUWE). Analysts rate AngioDynamics, Inc. (ANGO) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NUWE or ANGO?
Over the past 5 years, AngioDynamics, Inc.
(ANGO) delivered a total return of -53. 3%, compared to -100. 0% for Nuwellis, Inc. (NUWE). Over 10 years, the gap is even starker: ANGO returned -9. 2% versus NUWE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NUWE or ANGO?
By beta (market sensitivity over 5 years), Nuwellis, Inc.
(NUWE) is the lower-risk stock at 1. 11β versus AngioDynamics, Inc. 's 1. 32β — meaning ANGO is approximately 19% more volatile than NUWE relative to the S&P 500.
04Which is growing faster — NUWE or ANGO?
By revenue growth (latest reported year), AngioDynamics, Inc.
(ANGO) is pulling ahead at -3. 8% versus -5. 4% for Nuwellis, Inc. (NUWE). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -217. 4% for Nuwellis, Inc.. Over a 3-year CAGR, NUWE leads at -1. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NUWE or ANGO?
AngioDynamics, Inc.
(ANGO) is the more profitable company, earning -11. 6% net margin versus -211. 8% for Nuwellis, Inc. — meaning it keeps -11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANGO leads at -13. 7% versus -134. 3% for NUWE. At the gross margin level — before operating expenses — NUWE leads at 62. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NUWE or ANGO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NUWE or ANGO better for a retirement portfolio?
For long-horizon retirement investors, Nuwellis, Inc.
(NUWE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). Both have compounded well over 10 years (NUWE: -100. 0%, ANGO: -9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NUWE and ANGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(NUWE: 4.4% · ANGO: 9.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.